What is Zacks Research’s Forecast for CPRX Q1 Earnings?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Equities researchers at Zacks Research increased their Q1 2026 earnings per share estimates for shares of Catalyst Pharmaceuticals in a research report issued on Wednesday, March 18th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of $0.57 for the quarter, up from their prior estimate of $0.53. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.90 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q2 2026 earnings at $0.58 EPS, Q4 2026 earnings at $0.67 EPS, FY2026 earnings at $2.48 EPS, Q1 2027 earnings at $0.71 EPS, Q2 2027 earnings at $0.69 EPS, Q4 2027 earnings at $0.67 EPS and FY2027 earnings at $2.76 EPS.

CPRX has been the subject of a number of other research reports. Citigroup increased their price objective on shares of Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. Weiss Ratings reiterated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research report on Monday, December 29th. Two investment analysts have rated the stock with a Strong Buy rating and three have given a Buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $34.00.

Catalyst Pharmaceuticals Price Performance

CPRX opened at $22.79 on Monday. Catalyst Pharmaceuticals has a fifty-two week low of $19.05 and a fifty-two week high of $26.58. The firm’s fifty day moving average price is $23.95 and its two-hundred day moving average price is $22.59. The company has a market capitalization of $2.78 billion, a P/E ratio of 13.49, a P/E/G ratio of 0.66 and a beta of 0.75.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Deerfield Management Company L.P. boosted its stake in Catalyst Pharmaceuticals by 72.8% in the third quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock worth $98,003,000 after purchasing an additional 2,095,291 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 233.9% in the second quarter. American Century Companies Inc. now owns 1,757,988 shares of the biopharmaceutical company’s stock valued at $38,148,000 after buying an additional 1,231,419 shares during the last quarter. Janus Henderson Group PLC lifted its position in Catalyst Pharmaceuticals by 200.6% during the 4th quarter. Janus Henderson Group PLC now owns 1,719,767 shares of the biopharmaceutical company’s stock worth $40,124,000 after buying an additional 1,147,565 shares in the last quarter. Morgan Stanley lifted its position in Catalyst Pharmaceuticals by 59.1% during the 4th quarter. Morgan Stanley now owns 2,933,399 shares of the biopharmaceutical company’s stock worth $68,466,000 after buying an additional 1,089,775 shares in the last quarter. Finally, Fundsmith LLP grew its holdings in Catalyst Pharmaceuticals by 24.2% during the 3rd quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock worth $66,267,000 after acquiring an additional 654,721 shares during the last quarter. 79.22% of the stock is owned by institutional investors and hedge funds.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).